As of May 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, with a public comment period closing June 29, 2026
For patients on Wegovy with risk factors, monitoring should be individualised based on clinical need, with repeat testing after medication changes, during significant gastrointestinal illness, or if symptoms develop, rather than at fixed intervals
Among the 5,442 GI adverse events reported to the FDA, eructation had a reporting odds ratio of 42.03
The detailed breakdown in the AOD 9604 side effects guide covers everything reported in clinical and anecdotal settings
Digital Life, Thinking about Future 02:20:10 Worry, Meditation 02:24:22 Beliefs, God